Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Imp, it is clear that PS Targeting IP was a disturbance / paradigm shift / etc as explained in the prior post...specifically how BPs have up to 12 patents for each PS receptor targeted and multiply that by multiple drugs for multiple BPs for not only PS receptors but other MOAs that may not even do what the MOA says (3D live cellular imaging seeing down to protein pathway levels will change the way MOA are understood and that is yet another paradigm shift nearing )
It is nearing...that the Targeting of flipped PS happens 1st ...before the Cascade of other events play out
...back to your question
Nice conference call as they are trying so nicely, as legal as possible, to hide the IP assets that will dwarf CDMO profits that are not based upon IP of PS Targeting. Flipped PS begins 20 years earlier for Alzheimer's etc before any signs are picked up by your MD
That is a lot of CDMO business as the time is nearing.
_______
Role of Tumor Necrosis Factor in Neurodegeneration
published May 28, 2019
...
...
...
Apoptosis and necroptosis: Apoptosis is a form of programmed cell death mediated by caspases. Morphological features of apoptosis include expulsion of phosphatidylserine (PtdSer) to the outer side of the plasma membrane, chromatin condensation and DNA cleavage. Exposure of PtdSer to surface signals macrophages and other phagocytic cells to clear the debris.
In contrast Necroptosis is a form of Ne- crosis where plasma membrane permeability increases and organelle swells, this process is not mediated by caspases. Both apoptosis and necroptosis are reported during activation of TNF-a mediated pathway in the CNS [8].
...
...
Alzheimer’s Diseases (AD), Parkinson’s Disease (PD), Multiple Sclerosis (MS), Cerebral Ischemia (CI) and Amyotrophic Lateral Scle- rosis (ALS), traumatic brain injury (TBI), epilepsy are some of the major Neurodegenerative diseases where TNF- a is directly involved. Apart from these major diseases some other less common diseases like Creutzfeldt-Jakob’s disease (CJD), Huntington’s disease (HD), lysosomal storage diseases (LSDs), are also seen in individuals where TNF-a act as a prime factor in progression of that particular disease. We are discussing involvement of TNF-a and its receptors only in few major neurodegenerative diseases.
...
...
https://www.ecronicon.com/ecemr/pdf/ECEMR-04-00098.pdf
_____
After Dr. Wolchok's finding and publication/presentations on the subject, PPHM PdtSer-Targeting is the perfect replacement for OX40 and alikes in CAR-T for all solid cancers. ex-CEO King said renewed interest and Dr/ Wolchok said a test on humans is designed and waits for the company (understand->'the green light') to start.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137369922
_____
It was nice to hear the new CEO say one of the reasons Avid is so successful is due to its past history. Steve King was part of all that and even SK knew Alzheimer's etc would be treated ...required to be treated with PS Targeting
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=123918105
____
One has to ask themselves why there was no mention on the conference call regarding IP assets that will have quantum leap rise levels of knowledge and maybe Roger Lias was booted off as CEO due to him saying PS Targeting had residual value ?
Maybe now the BODs were told by legal they should not answer the IP asset valuation questions and analysts were forewarned ?
Maybe now, investors will like the CDMO valuation being staged, as the IP is being controlled in the background. Think about it...no longer would DOZENS of "key" FDA approved drugs be required with the introduction of PS Targeting.
Paradigm shifts scare the hell out of the Big Pharma aristocrats ( nice way of saying Mafia ) ... but knowledge continues to build and many a PhD will shake the tree that has fed Big Pharma for a hundred years and new seeds will be planted.
For residual value as Roger Lias said and voiced by Ronin Capital John Springs Stafford, why in the world would someone stealthily build / create a start up 30 days prior and come out of the blue to play let's make a deal with the IP assets ...as Oncologie Inc "backers" did.
Avid Bioservices NEVER mentioned or gave guidance to how much revenue comes now or future ...based upon the IP assets in the hands of Oncologie or UTSWM etc
____________
Of course some don't want to mention how the next Alzheimer's drug would be critical with PS Targeting and with Alzheimer's protein pathway changes about 20 years in advance, that is astronomical amount taking PS Targeting for treatment
___________
Good luck Eli Lilly and what is Steve Demattos brothers name again...oh yes, Ronald DeMattos! : )
Say hello to Cheryl Leyns at Merck ( Dr David Holtzman her advisor etc) as she knows Alzheimer's requires PS Targeting. Imagine that...some hedge funds spend hours trying to figure some of this out.
____________
- no 12 different drugs needed in I-O combination
...
...
PS both play roles in many biological processes, such as fibril formation in neurodegenerative diseases and wound healing.21,22
...
...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138657855
We shall see Cheynew but the new BODs have some explaining to do because the Preston pair may have some collusion going ons to help Merck / others
_____
March 5, 2018
BioDuro needs biomarkers ...and they pick up Molecular Response LLC
https://www.outsourcing-pharma.com/Article/2018/03/05/CDMO-BioDuro-acquires-Molecular-Response?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright
______
Jan 28, 2019
Advent’s strategic investment will strengthen BioDuro’s leadership position as a trusted global provider of drug discovery and development services
https://www.adventinternational.com/bioduro-partners-with-advent-international/
______
David Preston on one hand knows the value of biomarkers and CDMO BioDuro gets it
Heather Preston with Pivotal Bioventures sits poached up behind Oncologie and why was a deal not made directly with Peregrine and why the forced puppeteering act of John Springs Stafford ? Why would the new BODs not come out and say we have access to all biomarker data for our customers as BioDuro has done ??
Are there ulterior motives behind it all or does Chair Joseph Carleone finally wake up and give some insight on what the hell has been going on ??
Don't play down the IP Mr Carleone because we all will know how valuable those biomarkers are for Parkinson's Alzheimer's etc that Eli Lilly / Merck and competitors have going on....
We don't live in the 60's where information takes forever ...just man up and as for the CEO Rick ...he can come to the plate also and hit one out of the park or does that Standstill Agreement getting in the way of Fiducuary Duties ?? I hope not
Toss John Springs Stafford to the side....he may have got you all in there but it is now fiduciary duty time
John Springs Stafford feeling the heat and more is coming..
All should realize Steve Demattos has a very close tie with Ronald Bradley Demattos so why has the new BOD NOT done their fiduciary duties and look into everything as now they are officially going to be placed on warning that some are trying awfully hard to conceal the true value of the IP surrounding PS Targeting / biomarkers etc
Let us review and as you weave thru the puzzle pieces, Merck has an objective and it is to pick up all of PS Targeting IP value driver biomarkers via others help and that would be illegal to manipulate stock prices as John Springs Stafford is well aware
________
David M Holtzman on patents with Cheryl Leyns who is poached by Merck and yes, more to come
The new BODs have fiduciary duties to extract all values ...all avenues ...to maximize shareholder value and someone wants to buy out a CDMO because some want to HIDE the IP asset valuations behind biomarkers etc
Don't let it happen and all send in to IR that this is not acceptable
A bonus for you all: Heather Preston and David Preston ...some of it mentioned before but ties from Pivotal Bioventures to Advent International
https://www.adventinternational.com/bioduro-partners-with-advent-international/
First things first though.... the FBI investigations looked long into the DeMattos ...I certainly hope they are smarter than I
_________
No public announcement from the new BODs in regards to Steve Demattos departure of Pergrine Pharmaceuticals ? No excuse because the new BODs CAN NOT use the excuse that what happened in the past has no bearing now because it certainly matters. It matters because who knows what was concealed in the depositions or what trade secrets were use with Steve Demattos over at Xencor now ....the same Xencor and here John Stafford has left their BOD but buying up alot of Xencor stock this past year.....which all coincides with Stafford / Steve White with Ronin Hedge Group as it seems they are trying to conceal the true value of PS Targeting IP ...
Steve Demattos listed as contact for Xencor trial
Contact: Steve DeMattos, BS 858-480-3892 sdemattos@xencor.com
https://clinicaltrials.gov/ct2/show/NCT02725515
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138048080
_______
Ronald Bradley Demattos
age 49
Get Full Report on Ronald
ADDRESS HISTORY
Zionsville, IN
Fishers, IN
Noblesville, IN
Indianapolis, IN
Saint Louis, MO
Centereach, NY
Stony Brook, NY
East Setauket, NY
Port Jefferson Station, NY
Northville, MI
RELATIVES
Matthew Demattos
Yvonne Demattos
Abel Demattos
Steven Demattos
Alyssa Demattos
David Demattos
Shong Demattos
_________
Ronald DeMattos
Chief Scientific Officer Neurobiologics and Indianapolis Neuroscience Site Leader at Eli Lilly and Company
Indianapolis, Indiana Area
Pharmaceuticals500+
Summary
Ronald B. DeMattos, Ph.D. is currently a Chief Scientific Officer for Neurobiologics and Indianapolis Neuroscience Site Leader at Eli Lilly and Company. Dr. DeMattos received his doctorate in molecular and cellular biochemistry from State University of New York â?? Stony Brook in 1998. During his post-doctoral fellowship at Washington University School of Medicine (laboratory of David M. Holtzman), Dr. DeMattos performed the foundational studies that led to the development of the peripheral sink hypothesis for Alzheimerâ??s immunotherapy as well as the original antibody studies that would eventually lead to Eli Lillyâ??s Phase III drug candidate Solanezumab. Dr. DeMattos was recruited to Eli Lilly as a Research Scientist in 2002 and he has subsequently been promoted six times. He has led multiple successful programs targeting Alzheimerâ??s disease (compounds in Phase-1 and Phase-3) and he has played a major role in expanding the immunotherapy platform. Under Dr. DeMattosâ??s leadership, his team has provided many important deliverables for the Neuroscience division wherein they have developed scientific rationale, identified biomolecules, developed and performed innovative SAR, delivered key proof of concept data, and championed several large molecules through all phases of development (one of which is currently in Phase III clinical trials). Dr. DeMattos has developed the scientific rationale and corresponding assays to support clinical biomarker studies (7 different validated biomarker assays have been utilized in the clinic). Dr. DeMattos has played a key role in developing Lillyâ??s Alzheimerâ??s strategy and he has been a key resource for numerous functions beyond discovery. Dr. DeMattos currently leads the Indianapolis Neuroscience site comprised of talented scientists and staff whose mission is to develop novel first-in class therapies for Neuroscience indications, with significant emphasis on neurodegeneration and Alzheimerâ??s disease.
Specialties: Alzheimer's disease, drug development, clinical biomarker development, preclinical to clinical translational studies, in vivo pharmacology, lipoprotein biology, immunotherapy, pharmacology and biochemistry,
Experience
Image for Chief Scientific Officer Neurobiologics and Indianapolis Neuroscience Site Leader
Chief Scientific Officer Neurobiologics and Indianapolis Neuroscience Site Leader
Eli Lilly and Company
June 2002 â?? Present 17 years 1 month
Image for Instructer in Neurology
Instructer in Neurology
Washington University School of Medicine
June 1999 â?? June 2002 3 years 1 month
People also viewed
J. Carmel Egan
Associate Dean for Research Affairs , IU School of Medicine and COO Indiana CTSI
Henry Bryant
Distinguished Research Fellow at Lilly Research Laboratories
Janelle Sabo
Global Head, Product Delivery at Eli Lilly and Company
Bradley Miller MD, PhD
Senior Managing Director in Neuroscience
Charles Mitch
Eli Lilly (retired)
Jeffrey Witkin
Chief Executive Officer at Witkin Consulting Group
Patrick May
President at ADvantage Neuroscience Consulting LLC
Juan Jose Carrillo
Director at Eli Lilly and Company
Francis Willard
Research Scientist at LRL
Larry Blaszczak
Independent Pharmaceutical Consultant, Indianapolis Indiana Area.
_______
Top co-authors (50)
David M Holtzman
Washington University in St. Louis
Steven M Paul
Kelly Bales
Roche Pharma Research & Early Development
Margaret M. Racke
Robert A Dean
Eli Lilly
Affiliations
Eli Lilly and Company
United States Naval Research Laboratory
Philipps University of Marburg
University of Illinois at Chicago
Indianapolis Zoo
University of British Columbia - Vancouver
Department
Department of Pathology and Laboratory Medicine
Columbia University
Eli Lilly
Department
Lilly Research Laboratories
Duke University
Department
Department of Medicine
Indiana University-Purdue University Indianapolis
Department
Department of Psychiatry
Carnegie Mellon University
Department
Department of Chemistry
Washington University in St. Louis
Department
Department of Neurology
University of California, San Diego
State University of New York
Hackensack University Medical Center
Massachusetts Institute of Technology
Department
Department of Biology
https://www.google.com/amp/s/www.researchgate.net/scientific-contributions/39737839_Ronald_B_DeMattos/amp
Nice try but the fact is the 42,000 expansion space is ready to go live
Threes, my post was simply pointing out the Friday after hours Russell rebalance and I was not suggesting Avid had bad news.
It will be interesting to see Friday action.
In the meantime why did Mike Faughnan leave WuXi Apptec for little old Avid
A big plus, Archie Turner says "Represented Manufacturing in Change Control Review meetings as the primary departmental Engineering Change Request author in order to ensure efficient and timely release of equipment for GMP use" looks like any issues were resolved and ready for prime time
I hope so...since he got a promotion
All they have to say is admit that some seemed to have taken extraordinary steps to get close with PS Targeting ...even the one that shook up the BOD - John Springs Stafford
Good luck to all
Interesting with how they want to give updates the day before Russell rebalance
Friday after hours should be larger than normal volume
Looks like they wanted to keep this below $5 leading into end of June
Mark Foletta at Dexcom brought in Andrew Atilla Pal as Donald Bollella split to Skyworks and Ramon Valencia to Zumutor as Brigitte Phan stayed with Allergan
Lots of Apple devices need sensors/frequency drivers to detect flipped PS via monitor ?
Glucose is just the tip of the iceberg I say.. and so many more need flipped PS to monitor
BP has to make capitol allocation decisions as well? I agree ...some even play illegally in the sandbox
It has always been about the IP of PS Targeting
Sandbox is a term BPs use in order to share market access and a nod and a hint to stay in their hood so to speak and not move into another's market. The FBI emails being amassed details many things and is the reason why things are surfacing. Steve King knew of the FBI involvement and each time it was brought up in the way past...many here did not accept it.
It is bigger than most imagine and they are not looking to steal a CDMO that is for sure. A CDMO is just a way to promise business and manufacturing services for something else : )
I guess since it is public now, NIH has 61 Institutions under watch and FBI leaks to MD Anderson starting off with a couple dozen MDs researchers etc with full access to emails etc ... we have an astronomical amount of emails
Sandbox
PS Targeting
CDMO promised business in exchange for what?
It may (unlikely) even turn out that Oncologie was a way to steer PS Targeting into the lesser of two evils
Either way, things were not done right and John Springs Stafford not being honest but then again we have Sard Verbinnen in the mix and they boast about creating false impressions and try to make it sound true
You think Mologen would allow a third party to verify MGN1703 MOA
You think Biothera would allow a third party to verify Imprime PGG MOA?
Some say no BP interest, but there was highly enough interest to form Oncologie Inc and recruit some puppets in 30 days...all while big investors want to remain undisclosed lol
Yes, sure sounds like no big interest : )
How many emails mention sandbox and relate to PS Targeting, in FBI control and did they ever find the real reason why Dr Rolf Brekken went to China leading up to a Oncologie deal? Hmmm
Capital Allocation decisions by BP to who pays Gerald Finken CEO of CSM goes to GPP Great Point Partners
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133312643
Has John Springs Stafford been Avid Bioservices shareholders best interests in mind or would his interests be more aligned with Merck partners trying to sneak PS Targeting IP in house?
How many believe Merck do not advance certain programs properly?
Avid client Acumen (Goure) even agrees and with PS Targeting? I don't trust Merck at all
_______
“We were concerned that Merck wasn’t advancing our program as fast as we thought they should have,” Goure said.
https://medcitynews.com/2013/05/after-a-restructure-and-an-axed-merck-deal-acumen-gains-20m-for-novel-alzheimers-drug/
Bfiest, does it seem strange that Stephen White and John Stafford III never came back with a shareholder letter after they shook up the BOD?
I remember Acumen Pharma was one that selected Avid but I wonder why and how the undisclosed findings of the past may help prove how big PS Targeting always was.
Undisclosed...one word I think always leads to Merckly findings
______
Acumen Pharmaceuticals Lands Series A Financing
Date
4/27/2013
Company Name
Acumen Pharmaceuticals
Mailing Address
4435 North First Street Livermore, CA 94551
Company Description
Acumen Pharmaceuticals, Inc. is a biotechnology company developing disease modifying medicines and diagnostics for Alzheimerâ??s disease. Acumen Pharmaceuticals Inc. is engaged in the discovery and development of therapeutics and diagnostics related to soluble AÃ? oligomers in Alzheimerâ??s disease.
Website
http://www.acumenpharm.com
Transaction Type
Venture Equity
Transaction Amount
Undisclosed
Transaction Round
Series A
Proceeds Purposes
The capital will fund preclinical and potentially early clinical development of ACU-193, which selectively binds to and captures soluble oligomers of the amyloid-beta peptide.
M&A Terms
Venture Investor
Undisclosed
https://xconomy.com/san-francisco/2013/04/27/acumen-pharmaceuticals-lands-series-a-financing/
______
The trouble is....Merck (like many in Big Pharma) may not even realize the puzzle pieces that slowly appear and John Stafford lying to shareholders ? Not so nice
PS Targeting and the IP all are after
______
March 1, 2018
Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of Novel Alzheimerâ??s Disease Candidate
https://www.globenewswire.com/news-release/2018/03/01/1402176/0/en/Avid-Bioservices-Selected-by-Acumen-Pharmaceuticals-to-Lead-Process-Development-and-Clinical-Manufacture-of-Novel-Alzheimer-s-Disease-Candidate.html
________
Patents for William F Goure ...with big ties to Merck and Acumen (Merck has explaining to do but emails don't lie and 3D images further don't lie how well PS Targeting primes and prepares ones immune system)
Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
Patent number: 9320793
Abstract: This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.
Type: Grant
Filed: December 4, 2012
Date of Patent: April 26, 2016
Assignees:
Acumen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp.
Inventors: William F. Goure, Franz F. Hefti, Renee C. Gaspar, Paul J. Shughrue, Fubao Wang, Weirong Wang, Ningyan Zhang, Wei-Qin Zhao, Alexander McCampbell, Min Xu
____
Antibodies, kit and method for detecting amyloid beta oligomers
Patent number: 9310383
Abstract: This invention is a selective A? oligomer kit and immunoassay method capable of reliably and sensitively detecting A? oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A? oligomer antibodies, as capture and detection antibodies, to detect and quantify A? oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.
Type: Grant
Filed: June 3, 2015
Date of Patent: April 12, 2016
Assignees:
Acumen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp.
Inventors: William F. Goure, Renee C. Gaspar, Alexander McCampbell, Mary J. Savage, Paul J. Shughrue, Fubao Wang, Weirong Wang, Abigail L. Wolfe, Ningyan Zhang, Wei-Qin Zhao, Min Xu
...
...
https://patents.justia.com/inventor/william-f-goure
________
Acumen Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics and diagnostics for treating Alzheimerâ??s disease and related neurodegenerative conditions. The company focuses on developing ADDL-Select antibodies that target soluble AÃ? oligomers, which are main causes in the disease process. It also uses a sensitivity assay to measure soluble AÃ? oligomer levels in the cerebrospinal fluid in patients to be enrolled in clinical trials. Acumen Pharmaceuticals, Inc. was founded in 1996 and is based in Livermore, California.
4435 North First Street
Suite 360
Livermore, CA 94551
United States
Founded in 1996
Phone:
925-368-8508
Fax:
925-605-3813
www.acumenpharm.com
Key Executives For Acumen Pharmaceuticals, Inc.
Mr. Daniel J. O'Connell
Chief Executive Officer, President and Director
Dr. Grant A. Krafft Ph.D.
Co-Founder, Chairman of the Board and Chief Scientific Advisor
Dr. Caleb E. Finch Ph.D.
Co-Founder and Member of Scientific Advisory Board
Dr. William F. Goure Ph.D.
Chief Operating Officer
https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=8539521
________
Alan Epstein also likes MDSCs and was he involved with any questioning from FBI at MD Anderson ?
Such a pivotal coincidence as Pivotal Bioventure that recruited Laura Benjamin to hide the IP of PS Targeting
____
Alan L. Epstein, M.D., Ph.D.
Professor of Pathology, USC Keck School of Medicine
Greater Los Angeles Area
Biotechnology300
Experience
Department of Pathology and Laboratory Medicine
Professor of Pathology, Department of Pathology and Laboratory Medicine
Keck School of Medicine of USC
1984 - Present 35 years
Greater Los Angeles Area
Active in the field of cancer immunotherapy including the development of antibody fusion proteins, immunoconjugates, and targeting antibodies to the tumor microenvironment. In addition, developed a new biomarker assay for cancer which quantitates myeloid derived suppressor cells as a measure of tumor burdern and recurrence using flow cytometry and antibodies developed in the laboratory.
Department of Medicine
Adjunct Professor, Department of Medicine
MD Anderson Cancer Center
1994 - Present 25 years
Houston, Texas Area
Founder
Pivotal BioSciences, Inc.
2001 - 2011 10 years
Greater Los Angeles Area
How about the freezing of CDMO stock if CHAIR Joseph Carleone or CEO Rick don't do something unless they say Oncologie must do something ...and if neither do anything, John Springs Stafford must come clean and admit his wrongdoings as the IP assets of PS Targeting are NOT being publically, fully advanced
Steve King was the one who got PS Targeting into many places including with ImmunoScore with Jerome Galon and Chair Carleone had done nothing for us so far
_____
European Inventor Award 2019: Recognition to exceptional inventors from Austria, France, Japan, the Netherlands and Spain
20 June 2019
The European Patent Office (EPO) today honoured exceptional inventors from Austria, France, Japan, the Netherlands and Spain with the European Inventor Award 2019 at a ceremony in Vienna. The laureates are recognised for their outstanding achievements in plastic recycling, cancer diagnostics, rechargeable battery technology, marine antifouling and DNA testing.
“The imagination, intellect and expertise on display at this year’s European Inventor Award are inspirational; all of the finalists and winners are pushing boundaries and achieving new heights in their respective disciplines,” said EPO President António Campinos at the Award ceremony. “These inventors’ stories also show how patent protection can help turn innovation into market success. What’s more, intellectual property rights are fuelling the European economy – industries that make high use of patents, trademarks and design rights contribute significantly to GDP, trade and job creation in Europe.”
Held at the Wiener Stadthalle, the Award ceremony, now in its 14th edition, was attended by some 600 guests from the fields of intellectual property, politics, business, science and academia. The finalists and winners were selected by an independent, international jury from a pool of hundreds of inventors and teams of inventors put forward for this year’s Award. The recipient of the Popular Prize was chosen by the general public through an online vote in the run-up to the ceremony.
Research
Jérôme Galon (France): Immunoscore®, a clearer cancer test
The French immunologist’s diagnostic tool assesses the risk of relapse in cancer patients. It uses digital images of tumour samples and advanced software to measure immune response. Galon’s invention is already in use at clinics around the world to improve the accuracy of prognosis for patients with colorectal cancer. Further information
https://brussels-express.eu/european-inventor-award-2019-recognition-to-exceptional-inventors-from-austria-france-japan-the-netherlands-and-spain/
____
Cancer test, plastic recycling win Europe inventor awards
19 hours ago
A diagnostic tool to assess the risk of a cancer relapse, machines for plastic recycling, an alternative to toxic ship paint— all were among the inventions honoured at the European Inventor Awards on Thursday.
Here is a closer look at the prize winners from Austria, France, Japan, the Netherlands and Spain. The annual awards launched in 2006 by the European Patent Office (EPO) were presented in Vienna.
Frenchman's cancer test
Jerome Galon's research started with the theory that stronger immune systems can help cancer patients survive longer and finally led to the Immunoscore cancer test.
Already in use at clinics around the world for colourectal cancer, the test aims to help doctors understand patients and their tumours better and prescribe the best treatment.
"It's opened up a whole new era—the era of anti-cancer immunity, which is now unfolding with immunotherapy," the French immunologist says.
The test uses digital images of tumour samples and advanced software to measure patients' immune responses.
Galon spent years on research, filing a patent application for the method as far back as 2005.
He won the prize in the "research" category.
https://www.google.com/amp/s/phys.org/news/2019-06-cancer-plastic-recycling-europe-inventor.amp
PS Targeting Sunrise data etc used in Immunoscore
The MOS of Bavi treated patients ...with primed immune system, that went on to Keytruda would likely be why the big interest in Merck and PS Targeting
Amazing though...no BP interest? Hmm, Dr Rolf Brekken may or may not have been aware of the FBI Investigations for advanced research into cures for cancer as with the PS Targeting IP
A reason may be that the IP had to be shifted into certain hands but Chair Joseph Carleone will have to support placing a freeze on the pps since things are becoming public information and the agreement that was signed with Ronin Capital which gave them pretty much the right to manipulate the stock at will...does not seem legal at all.
____
Expanding The Use of Immunoscore In Early Stage CRC
Published Jue 20, 2019
Jerome Galone PhD Research Director ..discusses ways to expand Immunoscore ..
A disconnect? I guess we can say that things are much bigger than they appear
It has always been about the IP and now with sources disclosing the Federal Investigations regarding cutting edge IP, which includes PS Targeting...I would wait for the dust to settle
Why did Ken Dart shut down Dart Neuroscience?
Why did Rolf Brekken make the trek to China?
Did Peregrine just give back the exosomes / IP back to a US institution?
Lots of questions and it had always been about the IP
_________
So let me understand, Avid BOD said no real interest from Big Pharma
China was interested though so Oncologie backers had to hide in some virtual array ghost like structure ...
Hold it...now Merck has some real interest with IO PS Targeting combos
Biomarkers being stealthy as exosomes held onto by Texas Board of Regents / UTSWM
Looks like lots of private meetings going on...even China requesting Dr Rolf Brekken, for no interest in the IP
Though now, new research says flipping PS is causing havoc
What will the FDA say to investigations?
Sounds like Merck trying to make some play in the sand box but there is always loose ends
Sean Bohen working for who now?
Sean profile says April 2019 end of a career at AstraZeneca and Merck using up more poaching monies
Sean knows well of PS Targeting
I don't understand how one would like the new CDMO manufacturing methods that attracted Halozyme, yet one fails to understand how imaging is at the forefront right now, and the FDA not yet ahead of the curve to use 3D live imaging to test MOA of drugs they approve.
Sounds like a little paradigm shift in Big Pharma looming around the corner and since many here have followed PS Targeting, many would welcome imaging to put to the test the MOA of a drug like PS Targeting. If one fails to see that link...maybe there is some conflicts of interest to see PS Targeting succeed.
Dana Farber and Gordon Freeman, Clive Wood ...never said that ship had sailed and we shall see what happens next.
Remember, collaborations and biomarkers learned via PS Targeting is linked to John Springs Stafford trying to steal the IP, even if he is just the get away driver for others behind Oncologie.
_________
Dana-Farber Scores Major Legal Victory On Cancer Drug Patents Likely Worth Billions
Tasuku Honjo, left, and Gordon Freeman (courtesy Bengt Nyman/Flickr and Dana-Farber Cancer Institute)
The Dana-Farber Cancer Institute on Friday scored a major victory in Boston federal court: a ruling that one of its researchers should be listed as an inventor on six patents believed to be worth billions of dollars.
The patents are connected to immunotherapy drugs, a powerful new type of cancer treatment that unleashes a patient's own immune system against cancer.
The legal crux of the case was a dispute over a collaboration between American researchers and Japanese researchers led by Nobel Laureate Tasuku Honjo of Kyoto University. Honjo was listed as inventor on the patents, but Dana-Farber argued that the Americans — Drs. Gordon Freeman and Clive Wood — deserved to be listed on the patents as well.
One lawyer compared the case to deciding who gets credit for completing a jigsaw puzzle that includes many pieces put in by multiple players.
Given the financial stakes and the importance of the case, the verdict is likely to be appealed, says professor Jake Sherkow of New York Law School, an expert on patent disputes in the life sciences.
But at this point, "It's a total victory for Dana-Farber," he said on Friday.
"The judge's factual findings were particularly specific, and the conclusions of law were very thorough and well reasoned," he said. "So I think, given that, the likelihood of success on appeal is probably going to be scant," and the verdict is likely to stand.
One possible moral of the story, Sherkow said, is that "researchers who are engaged in long and detailed scientific collaborations with one another should be upfront about when, whether and to what extent they're applying for patents on what they view as their own contribution. Because in fact, that contribution may be a joint one."
The high-stakes legal drama pitted Honjo, 77, against another immunotherapy pioneer: Dana-Farber's Freeman, who's also a Harvard Medical School professor.
The trial focused on work done nearly 20 years ago, when some of the seminal science that led to immunotherapy was developed. The patents concerned what's called the "PD-1 pathway," which has become the basis for multiple immunotherapy drugs.
Dana-Farber, the plaintiff in the case, argued that the Americans made significant contributions and should be included on those patents. Honjo's side included the pharma giant Bristol-Myers Squibb, which now holds the licenses that control the use of those patents.
Honjo himself took the stand for hours and argued that no, he got no significant help from his American colleagues. Testimony at the trial focused heavily on the exchange of biological materials and unpublished data between the American and the Japanese researchers in 1999 and 2000.
The ruling by Judge Patti Saris reads, in part:
I find Dana-Farber has presented clear and convincing evidence that Dr. Freeman and Dr. Wood are joint inventors of the six Honjo patents. Dr. Honjo collaborated extensively with both Dr. Freeman and Dr. Wood from at least October 1999 until at least September 2000 through numerous meetings, joint authorship of scientific journal articles, written collaboration agreements, and sharing of experimental results and ideas. Indeed, Dr. Honjo himself referred to his work with Dr. Freeman and Dr. Wood as a collaboration on at least six occasions. While the relationship among these three brilliant scientists eventually soured, all three made significant contributions to the inventions.
Dana-Farber says in a press release:
The decision will enable Dana-Farber to license the technology, which is currently embodied in several of the newest immunotherapy drugs, to additional companies seeking to develop PD-1 and PD-L1 antibody therapeutics for a wide range of cancers.
https://www.google.com/amp/s/amp.wbur.org/commonhealth/2019/05/17/dana-farber-cancer-immunotherapycourt-victory
______
COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY
Publication number: 20150297677
Abstract: The invention provides methods, compositions, and kits featuring agents that inhibit viral entry mediated by T-cell Immunoglobulin and Mucin-domain containing proteins (TIM proteins) and other phosphatidylserine receptors.
Type: Application
Filed: December 12, 2013
Publication date: October 22, 2015
Applicant: Children Medical Center Corporation
Inventors: Hyeryun Choe, Stephanie Jemielity, Dale T. Umetsu, Rosemarie H. De Kruyff, Gordon J. Freeman
______
Sounds good and maybe CDMO could not sign on new customers as they need all the capacity they have, all of it, to fulfill demands that are nearing with Halozyme.
Now if John Springs Stafford can come clean about valuations behind PS Targeting. For Roger Lias to say no BP interest....Merck certainly has interest. 3D live imaging coming to the FDA and would the FDA change it's tune into how the MOA of a drug is verified?
Imaging ....tells all.
________________
Imaging is key and imaging at the cellular level proves PS Targeting patents are worth astronomical values to IO treatment. Can the Chinese or any other persuade researchers MDs etc for valuable information....sure, but all one needs is a sufficient imaging device to watch what happens when PS Targeting restores ones immune system and the dominoes that fall AFTER flipped PS is targeted just may disrupt BILLIONS of dollars in patents that only were awarded because a claim was made....ignoring the initial facts that flipped PS was targeted. Does the FDA verify these things upon ...before approval ? Amazingly not ...not good enough
Is John Springs Stafford good enough for shareholders? Not good enough
He should come clean and clean up his own mess, because he did not just show up for a CDMO
I doubt there are deals made for everyone, maybe the first ones to come clean may get a deal...who knows.
It looks like the Chinese knew all along how valuable PS Targeting would be...( don't forget Dr Rolf Brekkens trip to China that was reported before by a Chinese website and all of a sudden removed)
_________________________
ABOUT UNITED IMAGING
United Imaging Healthcare Technology Group Co., Ltd. develops and produces a full portfolio of advanced medical imaging and radiotherapy equipment and offers medical IT and intelligent solutions. Founded in 2011 and headquartered in Shanghai, the company has subsidiaries and R&D centers across China, US, and other parts of the world. UIH’s vision is to lead healthcare innovation and contribute to equal access to healthcare for all people worldwide. To learn more, visit https://www.united-imaging.com
https://usa.united-imaging.com/first-installation-of-umi-550/
________________________________
U.S. charges 3 NYU researchers in Chinese bribery case
Nate Raymond and Jonathan Stempel
NEW YORK (Reuters) - U.S. authorities brought criminal charges against three New York University researchers on Monday, alleging they conspired to take bribes from Chinese medical and research outfits for details about NYU research into magnetic resonance imaging technology.
A criminal complaint filed in the U.S. District Court in Manhattan charged Yudong Zhu, 44, Xing Yang, 31, and Ye Li, 31, with commercial bribery conspiracy in connection with NYU research financed by the U.S. government.
Federal prosecutors and the FBI said the three conspired to receive payments from a Chinese medical imaging company, United Imaging Healthcare, and a research institution supported by the Chinese government.
In exchange, prosecutors said, the defendants turned over confidential information about NYU research into MRI technology, which provides detailed views of the human body.
"As alleged, this is a case of inviting and paying for foxes in the henhouse," Manhattan U.S. Attorney Preet Bharara said in a statement. The alleged theft of research "is a serious crime and will not be tolerated by this office."
In addition to the bribery conspiracy count, Zhu was also charged with falsifying records in connection with a grant from the National Institutes of Health that a prosecutor said was worth $4 million.
Prosecutors said Zhu and Yang were arrested at their homes in New York on Sunday, while they said Li is believed to have flown to China on May 10 before charges were brought. Li could not immediately be located for comment.
NYU was not named in the complaint, which says the three individuals worked at a New York-based university research medical center. But a spokeswoman for the university confirmed the three defendants worked at the NYU Langone Medical Center.
"NYULMC is deeply disappointed by the news of the alleged conduct by its employees," Kathy Lewis, a university spokeswoman, said in a statement.
All three individuals have been suspended from NYU, Lewis said. The university is cooperating with the investigation, she said.
CHINESE CASES
The case comes amid heightened concern of Chinese theft of U.S. trade secrets. Prosecutors have brought several criminal cases against defendants accused of stealing trade secrets from the likes of Motorola Inc, General Motors Co and Dow Chemical Co and then providing them to Chinese companies.
Zhu, a Chinese citizen, was an associate professor in radiology at NYU; he was hired to teach about innovations in the MRI field in 2008, according to the complaint.
Richard Baum, a lawyer for Zhu, said at a hearing on Monday that by the time he joined NYU from General Electric Co, he was already "one of the world's renowned experts in MRI technology."
In 2010, Zhu applied for a grant from the National Institutes of Health. After starting research under the multimillion-dollar grant, prosecutors said Zhu recruited Yang and Li to work with him.
At that time, Zhu also arranged to receive financial benefits from an unnamed executive with United Imaging Healthcare, the complaint said.
The executive agreed to pay for Yang's graduate school tuition and Li's rent for his apartment, the complaint said. The executive also agreed to pay for their travel between China and New York, the complaint said.
Prosecutors said Yang also shared research results of his work with individuals at United Imaging.
Zhu, meanwhile, had been working with the United Imaging executive leading a similar MRI research project funded by the Chinese government, the complaint said.
Some of the defendants also had undisclosed connections to Shenzhen Institute of Advanced Technology (SAIT), a Chinese government-backed research institute also studying MRI technology, according to the complaint.
As part of an internal investigation NYU launched in connection with the case, Li allegedly told the university he had as of January 2013 been a research associate professor at SAIT.
Zhu, meanwhile, had worked with the unidentified United Imaging executive as part of the same MRI research team at the institute, the complaint said.
At a hearing to determine the defendants' bail, a U.S. prosecutor said the government had also since learned even more details about the crime not described in the complaint.
Zachary Feingold, an assistant U.S. attorney, said Zhu had told investigators that he received at least $400,000 from the Chinese company. The money was deposited in a bank account in the name of a company owned by his mother, Feingold said.
A call to United Imaging after business hours in China was not answered, nor was an email to the company. SAIT did not immediately respond to an email seeking comment.
PATENT AT ISSUE
Beyond the money from the Chinese company, the complaint also accused Zhu of intentionally failing to disclose an October 2008 patent application he filed for technology related to radio frequency coils used in MRI scanners.
https://www.google.com/amp/s/mobile.reuters.com/article/amp/idUSBRE94J0SC20130520
_______
The fraud will be exposed
No matter which ones are not really involved (think of the get away driver told to park around the block as some hop in the car with masks in hand ) but hey, he was only paid to drive and claims he did not know what was in those bags lol
...to those deeply involved and think of the emails being monitored. NO ONE knows to the extent how many dozens are on that FBI email list
You think Dr Jedd Wolchok was a bit curious after being questioned from many corners about PS Targeting as he was asked to steer away from PS Targeting ?
NO ONE knows the emails that were generated for a long time....
Has anyone ever mentioned requested all details in how the IP non disclosure agreements were not fully made public?
Has anyone ever questioned the Oncologie collaborations ?
Funny how all are concerned about CDMO contracts when PS Targeting is required for all those contracts ...
Has anyone ever questioned Dr Rolf Brekken in regards to MOA of various PS Targeting drugs?
I imagine emails will become important to refute what some claim that they were only paid to drive a car
Someone tried to drive away with the PS Targeting IP : )
Avid Bioservices receives royalties milestones net sale monies etc etc from Merck...I mean Oncologie
So do the BOD have fiduciary duty to make sure Oncologie lives up to the contract?
Should patents persuade Oncologie from halting full advancement of PS Targeting ?
Maybe we can ask Bronislaw Pytowski now working with Oncologie in NY but why NY?
________
The puzzle pieces to Merck build...and collaboration with Oncologie or against the full advancement of PS Targeting is the question
I have already proven Oncologie Laura E Benjamin ties to Biothera Mark T Uhlik etc etc and to Merck Michael Chisamore etc but Daniel J Hicklin I believe is another link to this Merck + Biothera ...to Oncologie initiative
Interesting times
___________
Bronislaw Pytowski
Top co-authors (50)
Kari Alitalo
Daniel J Hicklin
Yan Wu
Larry Witte
Kadmon Corporation
Kris Persaud
ImClone Systems
____________
The Blockbuster Drug Cyramza May Not Be The Savior Eli Lilly Was Hoping For
Jul. 1, 2015 5:30 AMEli Lilly and Company (LLY)
Summary
Cyramza has received four FDA approvals creating a large base of potential customers.
Cyramza faces stiff competition.
Cyramza alone will not be able to return Eli Lilly to its recent value.
Introduction
When Cyramza was initially approved for the treatment of stomach cancer in April of 2014, investors had high hopes for the drug. Just over a year later, Cyramza has seemingly succeeded having received a total of four FDA approvals. As Eli Lilly (NYSE: LLY) currently faces patent expirations and possible revenue loss, I am hopeful for resurgence, but I am not convinced that Cyramza will facilitate its second coming.
_____
Bronislaw (Bronek) Pytowski
Senior Director, Non-clinical research at Oncologie, Inc.
New York, New York
Biotechnology 457
Summary
Biotechnology professional with a proven drug development record from inception to clinical trials. I strongly believe in the importance of industry - academia collaboration and I have dedicated much of my professional time to initiating and managing such endeavors.
Professional highlight: The development of the monoclonal antibody ramucirumab (Cyramza®) from the initial identification of the target molecule, flk1/KDR (VEGFR-2), to global approval as a therapeutic agent in gastric, lung and colorectal cancers.
Significantly contributed to development of therapeutic monoclonal antibodies that target oncogenic tumor signaling, tumor angiogenesis and lymphangiogenesis. Most recently, led efforts to combine anti-angiogenic therapy with blockade of immunological checkpoints.
• Led ImClone Systems/Eli Lilly project teams for 25 years
• Formed advanced high-content in vitro imaging and screening team
• Formed and directed a high content, quantitative fluorescent microscopy team
• Contributed to pharmacodynamic and predictive biomarker discovery
• Established extensive network of academic collaborators in support of the Lilly portfolio
• Co-authored 58 research articles, 3 review articles and 3 book chapters
• 15 invited oral presentations at international scientific conferences
• Co-inventor on four ImClone Systems and Eli Lilly patents
I left Eli Lilly in in good standing in December 2017 by accepting a Voluntary Early Retirement offer. I am excited to continue contributing to drug development, once again in a small biotech company.
Experience
Image for Senior Director, Non-clinical research
Senior Director, Non-clinical research
Oncologie, Inc.
2018 – Present 1 year
Image for Senior Research Advisor
Senior Research Advisor
Eli Lilly and Company
January 2008 – December 2017 10 years
My principle role at Eli Lilly was that of non-clinical lead on the ramucirumab (Cyramza®) team. In this role, I directed non-clinical studies in support of the development of this monoclonal antibody as an anti-angiogenic agent for treatment of patients with solid tumors. My group:
• Developed in vitro assays for characterization of ramucirumab and several bi-specific antibodies containing a ramucirumab arm
• Developed in vivo strategies for modeling of combinatorial use of ramucirumab with standard-of-care chemotherapeutics, Lilly investigational molecules and immune checkpoint inhibitors
• Co-led in vivo studies in support of use of ramucirumab in in combination with immunological checkpoint inhibitors. Provided crucial mechanistic basis for the efficacy of this combination
• Explored potential biomarkers for anti-angiogenic therapy using animal models, patient plasma samples and patient tumor biopsies
I also established, managed, and coordinated an extensive network of academic collaborators in support of the Lilly portfolio of antibodies to VEGF family of receptors. I wrote all non-clinical sections of new drug applications (NDAs) for ramucirumab and provided support to the clinical and commercial teams through global presentations at conferences and internal training meetings.
Beyond ramucirumab, I initiated and directed investigational work on the VEGF receptor 3 antibody IMC-3C5 through phase 1/1b clinical trials. I coordinated internal and collaborative efforts to propose areas of clinical utility for this asset. I also provided non-clinical support for the team that developed an antibody to human VEGF receptor 1 (icrucumab) through phase 2 clinical trials. I also formed and directed a high content, quantitative, multi-parameter fluorescent microscopy team that provided extensive immunohistochemical data of tissues from proof-of-mechanism murine tumor studies of various Lilly assets.
_____
Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents
Article· Literature Review in Pharmacology [?] Therapeutics 164 · June 2016 with 28 Reads
DOI: 10.1016/j.pharmthera.2016.06.001
Beverly L Falcon
Sudhakar Chintharlapalli at Eli Lilly
Mark T Uhlik at Biothera
Bronislaw Pytowski
Abstract
Interaction of numerous signaling pathways in endothelial and mesangial cells results in exquisite control of the process of physiological angiogenesis, with a central role played by vascular endothelial growth factor receptor 2 (VEGFR-2) and its cognate ligands. However, deregulated angiogenesis participates in numerous pathological processes. Excessive activation of VEGFR-2 has been found to mediate tissue-damaging vascular changes as well as the induction of blood vessel expansion to support the growth of solid tumors. Consequently, therapeutic intervention aimed at inhibiting the VEGFR-2 pathway has become a mainstay of treatment in cancer and retinal diseases. In this review, we introduce the concepts of physiological and pathological angiogenesis, the crucial role played by the VEGFR-2 pathway in these processes, and the various inhibitors of its activity that have entered the clinical practice. We primarily focus on the development of ramucirumab, the antagonist monoclonal antibody (mAb) that inhibits VEGFR-2 and has recently been approved for use in patients with gastric, colorectal, and lung cancer. We examine in-depth the pre-clinical studies using DC101, the mAb to mouse VEGFR-2, which provided a conceptual foundation for the role of VEGFR-2 in physiological and pathological angiogenesis. Finally, we discuss further clinical development of ramucirumab and the future of targeting the VEGF pathway for the treatment of cancer.
https://www.google.com/amp/s/www.researchgate.net/scientific-contributions/38440419_Bronislaw_Pytowski/amp
______
Kadmon Corporation (originally Kadmon Pharmaceuticals) is a biopharmaceutical company based in New York City. It also has operations in Warrendale, PA and Brighton, MA. The company was founded in 2009 by Samuel D. Waksal,[2][3] founder and former CEO of ImClone Systems, now fully merged into Eli Lilly and Company. Waksal had served a federal prison sentence stemming from his fiduciary role as CEO in the 2001 ImClone stock trading case. When released in 2009 he was barred from serving as an officer for any publicly traded company but Kadmon was privately financed.[4][5]
https://en.m.wikipedia.org/wiki/Kadmon_Corporation
It would be nice if John Springs Stafford just came clean
The IP behind PS Targeting seems right up Tracy Saxton and Vincent Cheung alleys but Tracy only is listed under Pivotal Bioventure Partners from Jan 2017 till December 2017 so wonder what circumstances were playing out there and as for Stafford, I am sure email chains that web crawl from Biotech to bioteh to MD to researchers to hedge funds may be enough to force Stafford to talk because there is no way Stafford shows up to steer IP PS Targeting away from Dr Wolchok etc for no reason
____
With single Chinese investor, $300 million venture fund targets drug startups
Tracy Saxton, formerly an investor with Roche Venture Fund and SV Life Sciences and the industry alliances manager at UC's QB3 institute, is the founder and managing partner of Pivotal BioVenture Partners.
Ron Leuty, Reporter
Mar 16, 2017, 5:00am PDT
A new venture capital firm backed by a single Chinese investor is targeting early-stage drug companies with its inaugural $300 million fund.
Pivotal BioVenture Partners of San Francisco, led by a Roche Venture Fund veteran, is the latest in a string of life sciences VCs pulling in big money to invest in a range of drug, device and diagnostic companies. But unlike most funds, Pivotal is taking a longer, tougher road with its plan to invest $15 million-$20 million in 15-18 companies that haven't yet demonstrated proof of concept for their dream drugs.
"We're going back to basics — where are the advances, the fundamental needs — and doubling down on those types of opportunities," said Tracy Saxton, Pivotal's founder and managing partner.
Pivotal will do that with the backing of Nan Fung Group, originally a Hong Kong textile company whose investments have focused on real estate, hotels and shipping. Only in the past year or so has Nan Fung zeroed in on the life sciences, including as a limited partner in other venture funds; Pivotal, Saxton said, essentially becomes Nan Fung's U.S. and European therapeutics fund.
Nan Fung COO Vincent Cheung — the grandson of late company founder Chen Din Hwa and a former biochemistry student at the University of California, Berkeley — is Pivotal's managing partner.
The single-investor structure for a large venture fund is atypical. Funds, especially first-time funds by new VCs, often collect a handful of limited partners as investors, including pension funds, insurance companies and Big Pharma companies. Such a structure helps spread the investment risk.
But Saxton met Cheung this past summer, found a mutual interest in early-stage, innovative therapeutics and initiated talks about starting a fund, Saxton said. The deal closed in early January.
"Early stage" and "innovative" are two key terms for Pivotal. The fund, expecting to announce its first investment in a preclinical company yet this month, won't chase investments in cancer immunotherapy, the CRISPR gene-editing platform or other white-hot areas of commercial and academic interest. Instead, Saxton said, Pivotal may be interested in drugs that could play off broader advances in immunology brought about by cancer immunotherapy.
Saxton personally has an interest in immunology, infectious diseases, cancer and so-called orphan, or rare, diseases.
"We're fairly agnostic" as far as the types of disease targets, she said.
Yet Pivotal's focus always will be on early-stage companies that haven't yet reached human clinical trials or whose concepts haven't yet been borne out in those studies.
That investment philosophy would put it in the same strategic realm as some of the most well-respected biotech VCs, including Third Rock Ventures, ARCH Venture Partners and former Genentech research boss Dave Goeddel's The Column Group. Those three firms have offices within a few blocks of Pivotal's home at 1700 Owens St. in Mission Bay.
Most VC money, Saxton said, is flowing toward later-stage companies that have data from Phase II or Phase III studies, which place those companies relatively close to a Food and Drug Administration drug approval decision.
While early-stage companies are getting cash, innovation generally is not being rewarded with cash to move their therapeutics forward, she said.
There has been a wave of new fund announcements over the past several months, indicating that investors still are interested broadly in life sciences companies. San Francisco's Alta Partners, for example, hopes to raise $200 million for its next fund, and former Google Ventures chief Bill Maris will be the sole investor in a $100 million fund based in San Diego.
What's more, Biomatics Capital Partners — a Seattle firm run by Julie Sunderland, the former investment guru for the Bill & Melinda Gates Foundation, and Boris Nikolic, Bill Gates' former science advisor — launched a $200 million fund. And Third Rock said in October that it had raised a $616 million fund, its fourth and largest cache of cash.
With Saxton, Pivotal has a chance to sniff out early-stage science, startups and teams. Besides two years with the Roche Venture Fund, where she was embedded at the South San Francisco headquarters of biotech giant and Roche subsidiary Genentech Inc., she was an associate with SV Life Sciences for four years. She also was business development officer and director of alliance management at the California Institute for Quantatative Biosciences, or QB3, a University of California institute.charged with bringing discoveries from bench to bedside.
Prior to that, she worked at Tularik Inc., which was bought by biotech giant Amgen Inc., Threshold Pharmaceuticals and Geron.
"I've been in biotech for 17 years," she said. "I have relationships."
https://www.google.com/amp/s/www.bizjournals.com/sanfrancisco/news/2017/03/16/pivotal-bioventure-partners-nan-fung-group-roche.amp.html
_________
In some ways, Pivotal is the US-based extension of Nan Fung’s global biotech interests. And there’s something that Saxton and Cheung have in common. “We both like early-stage investments,” Saxton tells Endpoints News.
Later stages of more de-risked kinds of plays are already well funded in today’s biotech world, says Saxton, who is based in the Bay Area. She adds this new fund will back 15 to 18 new companies, with $15 million to $20 million per biotech.
CAR-T, immuno-oncology and CRISPR are all examples of the kind of advanced clinical-stage companies she probably wouldn’t get too involved in. But if you can take some new knowledge in, say, immuno-oncology and make it work in immunology, that might get her attention. Infectious diseases, immunology and rare diseases are all focuses she’s prepared to invest time and money in, from preclinical stages on through — possibly — going as late as Phase I. All of it, though, has to begin well ahead of proof-of-concept data.
https://endpts.com/new-biotech-venture-fund-debuts-with-300m-for-a-mix-of-us-and-european-players/
____________
John Springs Stafford and stock manipulation ? He already has a track record of employees that take pride in such acts ...and Brian Weston aka Black Rock Black Cloud friend in on it
You think they knew of all the emails being monitored ? I hope they continue their mission as one lie always leads to another
John Springs Stafford has not acted in shareholders best short term interest
Dr Jedd Wolchok spoke highly of PS Targeting and blocking off target toxicities are still big pieces of pipelines that must compete with others
None of Dr Wolchok research works have been tainted
The monies received by Dr Wolchok are to steer him in other directions ...for now
Dr Wolchok tied into the FBI MD Anderson emails ?
Hmmmm...let us wait and see what unfolds
Avastin was a double failure in its heyday when it broke free
PS Targeting will break free as well
I imagine some bosses emails are watched and monitored, as hedge funds tied to certain MDs etc etc : )
Good luck
Interesting times for sure
Avid Bioservices a CDMO with assets like no other CDMO
Anti-CD38 and other IO drugs, very likely must target flipped PS first before it continues on to realize its MOA ...so I ask, would HALO / JNJ and others realize this and to not upset the cartel too much make Avid a manufacturing CDMO it can not refuse ?
Whom is Oncologie dealing with?
How is China involved and scientists must be loathing over an IP that would disrupt he entire industry....but if Avid is guaranteed the proper royalties milestones etc etc etc from Oncologie etc and guaranteed all manufacturing ...then things become astronomical
I wonder what the FBI asked Rolf Brekken and many other ties into MD Anderson ...
attractive candidates..
Thanks Jakedogman1 and it would be of interest to have darzalex vs Bavituximab or other PS Targeting drugs side by side ....monitoring with a Keen Eye on the mechanism of actions of each and we shall see possibly, why Halozyme had chosen Avid as a key manufacturing facility for Billions of future revenue
____
________
CD38 is expressed on hematopoietic cells, other cell types and tissues, and is overexpressed on multiple myeloma cells1,2
DARZALEX® inhibits tumor cell growth through immune-mediated, direct on-tumor, and immunoregulatory actions.
DARZALEX® may also have an effect on normal cells1
https://www.darzalexhcp.com/mechanisms-of-action
_______________
If one drug such as Darzalex kicks off a series of events and flipping PS exists...well, one normally had to unlock the same series of events in reverse
So it would be of interest to see those MOA of many drugs and what happens if Targeting flipped PS is the FIRST order of event that takes place?
I have an idea....many sabotage attempts take place to delay its acceptance and maybe we now know why all the excitement over PS Targeting
_______________
CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
Fabio Morandi1*,
Alberto L. Horenstein2,3,
Federica Costa4,
Nicola Giuliani4†,
Vito Pistoia5† and
Fabio Malavasi2,3†
1Stem Cell Laboratory and Cell Therapy Center, Istituto Giannina Gaslini, Genoa, Italy
2Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Torino, Italy
3CeRMS, University of Torino, Torino, Italy
4Department of Medicine and Surgery, University of Parma, Parma, Italy
5Immunology Area, Pediatric Hospital Bambino Gesù, Rome, Italy
...
...
Anti-CD38 mAbs
Development of mAbs against CD38 started in 1990 and anti-CD38 mAbs have been tested as immunotherapeutic strategy for MM patients, so far with limited beneficial effects. The anti-tumor effect of anti-CD38 mAbs is related to their ability to induce ADCC, CDC and ADCP of opsonized CD38+ cells. Moreover, anti-CD38 mAbs can induce a direct apoptosis of CD38+ MM cells via Fc-? receptor-mediated crosslinking (24). Crosslinking of anti-CD38 mAbs on MM cells leads to clustering of cells, phosphatidylserine translocation, loss of mitochondrial membrane potential, and loss of membrane integrity.
...
...
https://www.frontiersin.org/articles/10.3389/fimmu.2018.02722/full
Awfully quiet period times here
Maybe Telegraph Hill Partners would have a Keen eye interest on Avid and PS Targeting Biomarkers
Very interesting to see more puzzle pieces surface with Akoya to Argonaut and Avids part time CEO can no way say he sees hardly no value in PS Targeting as John Springs Stafford had hinted to shareholders
https://thpartners.net/portfolio/
Would Argonaut be a good fit for Avid to buyout via shares?
PR new customer contracts with HALO etc
PPS to $10-20
Use that leverage to expand and buy someone out
They can buy someone bigger ...because Avid having some HALO business is big
This pps is behaving like those that had a hand in it for so long are like in a quiet period
Sooner or later it will change and as I see it... as long as the deal is structured with Oncologie I wonder if some BPs will begin to get their foot in the door with Avid before some PS Targeting approval
Trivia question ...how many times did Lisa Stepp visit Hopkinton MA Perkin Elmer site?
.. Cliff Hoyt..an interesting character
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131555041
I figure some should find it of interest that Cliff ends up with Akoya and Akoya has collaborations with some, including Argonaut where we have Rick Hancock that is Chair of the BOD there....
Mr Hancock certainly aware how big PS Targeting is and the Biomarkers derived out of all work groups
______
Let's recap ...who is leading the Immunoscore project and working with biomarkers with Peregrine?
Bernard Fox via Jerome Galon
...Cliff Hoyt and Lisa Stepp ... Nikoletta Kallinteris etc
How the world turns
______
March 22, 2019
Commercial launch of CODEX® System and Phenoptics™ 2.0 provide the most complete suite of tools for tissue biomarker discovery and translationSpatially resolved, multiplexed tissue imaging can unravel the complexities of the tumor microenvironment
...
...
Bernard Fox, PhD, at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center was one of the first researchers to apply the MOTiF technology to his studies.“With the advancement of so many new therapeutic options, it’s imperative that we address the critical need for identifying the right biomarkers to improve treatment outcomes for cancer patients,” he said. “The addition of MOTiF technology to Phenoptics now provides us the right platform that can help generate large-scale clinical trial data for the validation of new biomarkers. Our experience with the implementation of this technology makes me optimistic that we will soon have a solution to better stratify patients for clinical trials and ultimately provide tailored therapy that will result in improved patient outcomes.”
“Akoya is excited to bring unprecedented power, scale, and automation to histology through the power of multiplex immunofluorescence,” said Brian McKelligon, Chief Executive Officer of Akoya. “The commercial availability of CODEX is a major achievement for Akoya and the release of Phenoptics 2.0 underscores the successful and rapid integration of the Phenoptics division from PerkinElmer into Akoya. We are proud to establish our market leadership in high-parameter tissue analysis with these transformative tools and to catalyze scientists’ ability to identify predictive biomarkers.”
https://www.marketwatch.com/press-release/akoya-biosciences-launches-comprehensive-solution-for-high-parameter-tissue-analysis-2019-03-22
Some do not understand when a drug fails vs when a trial is stopped by Merckly friends ties into IDMC on Sunrise phase III
Cliff Hoyt biomarker data translational data guru working with Peregrine
Rick Hancock Chair of BOD at Argonaut and on BOD at Avid
Joseph Carleone Chair of BOD at Avid and ties to Sensient etc more
Conflicts of interest are ever increasing and John Springs Stafford squirming a bit more getting involved in all this I would think
___
Akoya Biosciences together with our strategic partners are leading the emerging field of tissue biomarker analysis.
Ultra-high multiplexing biomarker analysis and discovery
High-throughput workflows for true quantitative pathology
Revealing basic cell-to-cell biology in intact tissues
Stratification and drug mechanism of action in clinical trials
https://www.akoyabio.com/company/our-partners
PerkinElmer
PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $2.3 billion in 2017, has about 11,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index.
Argonaut Manufacturing Services, Inc.
Argonaut provides contract manufacturing in the life science and biotech arena for clients looking to leverage their supply chain. With experience supporting product launch, scale-up and revitalization, Argonaut houses over 7,500 sq.ft. of clean room production area and 3,000 sq. ft. of “research use only” manufacturing space at their headquarters in Carlsbad, CA. Argonaut is backed by the venture capital team, Telegraph Hill Partners.
BioLegend
BioLegend develops and manufactures world-class, cutting-edge antibodies and reagents at an outstanding value to customers for biomedical research. The broad product portfolio includes flow cytometry, cell biology, and functional reagents for research in immunology, cancer research, stem cells, and more. The aggressive product development program is accomplished through technology licensing, collaborations, and internal research. BioLegend offers a wide range of custom services, including assay development, sample testing, and conjugation. BioLegend headquarters in San Diego, CA operates under an ISO 13485:2003 certified quality management system.
Indica Labs Inc.
Indica Labs software solutions provide fast, quantitative evaluation of whole slide tissues using HALO and HALO AI for image analysis and HALO Link to manage images, data, and facilitate collaboration. With unmatched ease-of-use and scalability, pharmaceutical, healthcare, and research organizations worldwide are using HALO for high-throughput, whole-slide image quantification in areas such as oncology, immuno-oncology, neuroscience, ophthalmology, metabolism, respiratory and toxicological pathology.
Keyence
Keyence is a leading supplier of sensors, measuring systems, laser markers, microscopes, and machine vision systems worldwide, Keyence is at the forefront of factory automation. Keyence strives to develop innovative and reliable products to meet the needs of our customers in every manufacturing industry. Keyence has steadily grown since 1974 to become an innovative leader in the development and manufacturing of industrial automation and inspection equipment worldwide. Our products consist of code readers, laser markers, machine vision systems, measuring systems, microscopes, sensors, and static eliminators. Today, Keyence serves over 250,000 customers in 100 countries around the world, where our name stands for innovation and excellence. Keyence Corporation of America is located in Itasca, IL.
VIB
VIB, a life sciences research institute based in Flanders, Belgium, performs basic research with a strong focus on translating scientific results into pharmaceutical, agricultural and industrial applications.
Visiopharm
Visiopharm is a world leader in Augmented Pathology™ solutions. Leading biopharmaceutical companies, contract research organizations (CROs), academic medical centers, and hospital diagnostic pathology labs all over the world utilize the Oncotopix platform for tissue-based research and diagnostics. Oncotopix provides scientists and pathologists with a scalable software solution that fits the needs and volumes of both research and diagnostic labs. Over the past 16 years Visiopharm has grown into an international business with over 800 installations and countless more users. Visiopharm software is featured in over 1,350 scientific publications since 2010 and is compatible with leading slide scanning systems and data management software. A growing network of authorized distributors and integration partners support the growth of Visiopharm solutions on several continents including North America, Europe, and Asia. Our headquarters is in the Medicon Valley of Denmark, with a branch office in the United Kingdom and a North American office in Broomfield, Colorado.
Ximedica, Inc.
Ximedica is ISO 13485:2012 Certified and FDA Registered. As a full-service development firm, Ximedica has an exclusive focus on medical products and over 25 years of experience developing medical devices, combination products and consumer healthcare products.
_______
Mr. Richard B. Hancock, also known as Rick, serves as the Chairman of the Board and Executive Director of Argonaut Manufacturing Services, Inc. Mr. Hancock serves as Interim President and Chief Executive Officer of Avid Bioservices, Inc. since May 8, 2019. He has worked in the biologic contract development and manufacturing organization (“CDMO”) industry for over 30 years in various operational and executive roles.
....
....
....
________
Cliff Hoyt
Prior to joining Akoya Biosciences, Cliff was Director of Applications and Services for PerkinElmer’s Quantitative Pathology Business Unit. Cliff was co-founder and CTO of CRI, Inc., acquired by PerkinElmer in 2011. Since then, as Oncology Fellow, Cliff lead development of multiplexed staining methods (Opal), built the contract research business, partnered with pharma and academia to understand translational research and clinical needs and to advance adoption of multiplexed immunofluorescence methods, and worked with PKI business leaders to develop an oncology translational strategy. Cliff has been Principal Investigator on NIH SBIR grants, received his BA in Physics from Williams College in 1983 and MS in Mechanical Engineering from MIT in 1987, and is named inventor on over 20 patents.
In an exploratory analysis of OS for patients who received subsequent immune checkpoint inhibitors (ICI), the mOS was not reached (95% CI, 15.2-NA) in B+D (n=46) and 12.6mos. (95% CI, 10.4-17.8) in D (n=47) (HR=.46; P=.006).
PS Targeting and cumulative IP, and remember the CTO Confidential Treatment Order that does not go public till 2021 where some details of that Oncologie IP transfer were not fully disclosed
By: Eb0783 10-13-16 #275973
ASM attendees - roughly 40. 20 of us being shareholders.
FU/275979(re: Garnick?): He was a very valuable asset in the meeting.
FU/276020: From the ASM: King said (in answer to a question about B2GP1 stability, a la GJH) that B2GP1 is “relatively stable” among the patients and, although not as much is known about it compared to other proteins, there probably is no more than a +/-10% variation in a given patient.
Dr Garnick said that B2GP1 is only one (and maybe not the most important) of a number of biomarkers and they will have a number of them creating a profile. Lytle said the $$ spend on Sunrise will be finished by around end of calendar year. My take on these two statements is that they will have the analysis done and the biomarker profile will be complete. imo
Garnick shared a story about an early biomarker at Genentech with us that very few people know. Herceptin failed its first trials but one scientist identified the HER2 mutation and saw how many with HER2 lived longer. So they ran another trial which also failed. Garnick and his peers didn't believe in it but one other guy, identified a biomarker that corrolated with the ones who lived, and talked them into spending another $60mm on one more trial. Since then Herceptin has save 1000's of lives and earned $Billions of dollars. He believes in the value of biomarkers and he has been driving it for us.
As to my question of filing the BLA with what we have, [sorry CP, I did agree with your view) Dr Garnick point blank said our data is “not fileable.” We have now proof of concept and need now another trial, even a small phase II, to validate. Keep in mind however that means a smaller trial and with biomarkers involved it could be shorter than we imagine. imo
On a sidebar with just Shelley and I, Shelly Fussey said they have filed a detailed provisional patent on the Biomarkers which sets the filed date, keep it from being published/shared, and allows inexpensive additions/updates for a number of months (forget if it was 6, 9, or 12). Basically, we the public, and their competitors, will not be able to access it for 18mos. It also adds another year to the patent protection that way.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=126058658
We shall see Cheynew, but real news regarding Merck Ketruda
Common side effects of KEYTRUDA when given with certain chemotherapy medicines include feeling tired or weak, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, trouble breathing, fever, hair loss, and inflammation of the nerves that may cause pain, weakness, and paralysis in the arms and legs.
$3.9998 let's give a big round of applause to the hedge funds guru likes Brian Weston that program those algos for Ronin Capital and BlackRock ...very impressive lol
Avid Bioservices controlled at the moment by Ronin Capital _ John Springs Stafford and Steve White, where the heck did Mr White go? It will be interesting to see the names of the IDMC go public at some point and the data the IDMC had access to being used for Biomarkers via other FDA side channels
Damn, 15,329 shares as of now ... MIT specialists may even say that the float is lower than we all think as 60% IIS is higher than expected or who knows ...maybe John Springs Stafford begins to squirm a bit more